

SIX SIMPLE STEPS TO SUBMITTING A REFERRAL

1 PATIENT INFORMATION (Complete or include demographic sheet)

Patient Name:

Address: City, State, ZIP:

Preferred Contact Methods:

Phone (to primary # provided below) Text (to cell # provided below) Email (to email provided below)

Note: Carrier charges may apply. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.

Primary Phone: Alternate Phone: Date Of Birth:

Gender: Male Female Email:

Last Four of SSN: Primary Language:

2 PRESCRIBER INFORMATION

Prescriber's Name:

State License Number: NPI Number: DEA Number:

Group or Hospital: Address:

City, State, ZIP:

Phone: Fax:

Contact Person: Contact Phone:

3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: Ship to: Patient Office Other:

Diagnosis (ICD-10):

- K50.00 Crohn's Disease of Small Intestine Without Complications
- K50.10 Crohn's Disease of Large Intestine Without Complications
- K50.80 Crohn's Disease of Small & Large Intestine Without Complications
- K50.90 Crohn's Disease, Unspecified, Without Complications
- K51.00 Ulcerative (chronic) pancolitis without complications
- K51.30 Ulcerative (chronic) rectosigmoiditis without complications
- K51.50 Left sided colitis without complications
- K51.90 Ulcerative colitis, unspecified, without complications
- Other Code: Description:

Patient Clinical Information:

Allergies: Weight: lb/kg Height: in/cm

TB Test Result: Date:

Nursing:

Specialty pharmacy to coordinate injection training/ home health infusion nurse visit necessary Yes No

Site of Care: MD office Infusion Clinic Outpatient Health Home Health

Injection training not necessary. Date training occurred:

Reason: MD office training patient PT already independent Referred by MD to alternate trainer

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with **Linden Retail Specialty Pharmacy** and/or one of its affiliates.

Please complete Patient and Prescriber information

Patient Name:

Patient Date Of Birth:

Prescriber Name:

Prescriber Phone:

5 PRESCRIPTION INFORMATION

| MEDICATION | STRENGTH | DOSE & DIRECTIONS | QUANTITY/REFILLS |
|------------|---|--|--|
| Cimzia | Cimzia Starter Kit (6 prefilled syringes) | Induction Dose: Inject SC 400mg (2 injections) on day 1, and at weeks 2 and 4. If response occurs, follow with 400 mg every four weeks | Quantity: 1 kit (6 prefilled syringes) Refills: 0 |
| Cimzia | 200 mg/1 mL Prefilled Syringe 200 mg vial | Maintenance Dose: Inject SC 400 mg (2 injections) every 4 weeks. | Quantity: Refills: |
| Entyvio | 300 mg in a single dose vial in individual carton | Recommended dosage in UC & CD: 300 mg infused IV over 30 minutes at 0, 2 and 6 weeks, then every 8 weeks thereafter. | Quantity: Refills: |
| Humira | Crohn's Disease, Ulcerative Colitis 40 mg/0.4 mL Starter Package Citrate Free Crohn's Disease, Ulcerative Colitis 80 mg/0.8 mL and 40 mg/0.4 mL Starter Package Citrate Free | Induction Dose: Inject SC 160 mg on day 1, then 80 mg on day 15, then maintenance on day 29 | Quantity: 1 package Refills: 0 |
| Humira | 40 mg/0.4 mL Pen Citrate Free 40 mg/0.4 mL Prefilled Syringe Citrate Free | Maintenance Dose: Inject one 40 mg pen/syringe SC every other week | Quantity: Refills: |
| Inflectra | 100 mg vial | Induction Dose: IV at 5 mg/kg (Dose = mg) at week 0, week 2, week 6 and every 8 weeks thereafter Maintenance Dose: IV at 5 mg/kg (Dose = mg) every 8 weeks. Other: | Quantity: # of 100 mg vial Refills: |
| Remicade | 100 mg vial | Induction Dose: IV at 5 mg/kg (Dose = mg) at week 0, week 2, week 6 and every 8 weeks thereafter Maintenance Dose: IV at 5 mg/kg (Dose = mg) every 8 weeks. Other: | Quantity: # of 100 mg vial Refills: |
| Renflexis | 100 mg vial | Induction Dose: IV at 5 mg/kg (Dose = mg) at week 0, week 2, week 6 and every 8 weeks thereafter Maintenance Dose: IV at 5 mg/kg (Dose = mg) every 8 weeks. Other: | Quantity: # of 100 mg vial Refills: |

5 PHYSICIAN SIGNATURE REQUIRED

Product Substitution Permitted

(Date)

Dispense as Written

(Date)

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with **Linden Retail Specialty Pharmacy** and/or one of its affiliates.

Please complete Patient and Prescriber information

Patient Name:

Patient Date Of Birth:

Prescriber Name:

Prescriber Phone:

5 PRESCRIPTION INFORMATION

| MEDICATION | STRENGTH | DOSE & DIRECTIONS | QUANTITY/REFILLS |
|------------|--|--|--|
| Cimzia | Cimzia Starter Kit (6 prefilled syringes) | Induction Dose: Inject SC 400mg (2 injections) on day 1, and at weeks 2 and 4. If response occurs, follow with 400 mg every four weeks | Quantity: 1 kit (6 prefilled syringes) Refills: 0 |
| Cimzia | 200 mg/1 mL Prefilled Syringe 200 mg vial | Maintenance Dose: Inject SC 400 mg (2 injections) every 4 weeks. | Quantity: Refills: |
| Entyvio | 300 mg in a single dose vial in individual carton | Recommended dosage in UC & CD: 300 mg infused IV over 30 minutes at 0, 2 and 6 weeks, then every 8 weeks thereafter. | Quantity: Refills: |
| Humira | Crohn's Disease, Ulcerative Colitis 40 mg/0.4 mL Starter Package Citrate Free Crohn's Disease, Ulcerative Colitis 80 mg/0.8 mL and 40 mg/0.4 mL Starter Package Citrate Free | Induction Dose: Inject SC 160 mg on day 1, then 80 mg on day 15, then maintenance on day 29 | Quantity: 1 package Refills: 0 |
| Humira | 40 mg/0.4 mL Pen Citrate Free 40 mg/0.4 mL Prefilled Syringe Citrate Free | Maintenance Dose: Inject one 40 mg pen/syringe SC every other week | Quantity: Refills: |
| Inflectra | 100 mg vial | Induction Dose: IV at 5 mg/kg (Dose = mg) at week 0, week 2, week 6 and every 8 weeks thereafter Maintenance Dose: IV at 5 mg/kg (Dose = mg) every 8 weeks. Other: | Quantity: # of 100 mg vial Refills: |
| Remicade | 100 mg vial | Induction Dose: IV at 5 mg/kg (Dose = mg) at week 0, week 2, week 6 and every 8 weeks thereafter Maintenance Dose: IV at 5 mg/kg (Dose = mg) every 8 weeks. Other: | Quantity: # of 100 mg vial Refills: |
| Renflexis | 100 mg vial | Induction Dose: IV at 5 mg/kg (Dose = mg) at week 0, week 2, week 6 and every 8 weeks thereafter Maintenance Dose: IV at 5 mg/kg (Dose = mg) every 8 weeks. Other: | Quantity: # of 100 mg vial Refills: |

5 PHYSICIAN SIGNATURE REQUIRED

Product Substitution Permitted

(Date)

Dispense as Written

(Date)

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with **Linden Retail Specialty Pharmacy** and/or one of its affiliates.

Please complete Patient and Prescriber information

Patient Name:

Patient Date Of Birth:

Prescriber Name:

Prescriber Phone:

5 PRESCRIPTION INFORMATION

| MEDICATION | STRENGTH | DOSE & DIRECTIONS | QUANTITY/REFILLS |
|------------|--|---|--|
| Inflectra | 100mg/mL in a single-dose prefilled SmartJect® autoinjector 100 mg/mL in a single-dose prefilled syringe | Induction Dose: Inject SC 200 mg initially (given as 2 subcutaneous injections of 100 mg each) at Week 0, followed by 100 mg at Week 2 and then 100 mg every 4 weeks Maintenance Dose: Inject SC 100 mg every 4 weeks Other: | Quantity: Refills: |
| Stelara | 130 mg/26 mL (5 mg/mL) IV single-dose vial Date Infusion was completed or scheduled: . (This date is needed to determine shipment of Stelara SC maintenance dosage) | Single IV Induction Dose: 55 kg or less 260 mg at Week 0: # of vials to be used 2 more than 55 kg to 85 kg 390 mg at Week 0: # of vials to be used 3 more than 85 kg 520 mg at Week 0: # of vials to be used 4 Other: | Quantity: 2 Vials 3 Vials 4 Vials Refills: 0 |
| Stelara | 90 mg/mL SC dose in a single-dose prefilled syringe | 90 mg SC dose 8 weeks after the initial IV induction dose, then every 8 weeks thereafter Other: | Quantity: Refills: |
| Tysabri | NA | Please complete a MS TOUCH®/Tysabri enrollment form and indicate Linden Retail Specialty Pharmacy as your preferred pharmacy provider. (For questions, please contact TOUCH Prescribing Program at 1-800-456-2255) | Quantity: 0 Refills: 0 |
| Xeljanz | 5 mg 10 mg | 10 mg twice daily for at least 8 weeks; followed by 5 or 10 mg twice daily, depending on therapeutic response. Use the lowest effective dose to maintain response. Discontinue Xeljanz after 16 weeks of treatment with 10 mg twice daily, if adequate therapeutic benefit is not achieved. Other: | Quantity: Refills: |

Complete Items below, required for Home Infusion/Coram AIS:

| MEDICATION / SUPPLIES | ROUTE | DOSE & DIRECTIONS | QUANTITY/REFILLS |
|-------------------------------------|----------|---|---------------------------|
| Catheter PIV PORT PICC | IV | Catheter Care/Flush – Only on drug admin days – SASH or PRN to maintain IV access and patency PIV – NS 5ml (Heparin 10 units/ml 3-5ml if multiple days) PORT/PICC – NS 10ml & Heparin 100units/ml 3-5ml, and/or 10ml sterile saline to access port a cath | Quantity: Refills: |
| Epinephrine **nursing requires** | IM SC | Adult 1:1000, 0.3mL (>30kg/>66lbs) Peds 1:2000, 0.3mL (15-30kg/33-66lbs) Infant 0.1mL/0.1mL, 0.1mL (7.5-15kg/16.5-33lbs) PRN severe allergic reaction – Call 911 May repeat in 5-15 minutes as needed | Quantity: Refills: |

5 PHYSICIAN SIGNATURE REQUIRED

Product Substitution Permitted

(Date)

Dispense as Written

(Date)

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with **Linden Retail Specialty Pharmacy** and/or one of its affiliates.